Type 2 Diabetes

In part 5, the finale, of this Exclusive Interview, DIC publisher Steve Freed asks about the possibility of expanding the study of the nutritional supplement to address diabetic retinopathy.

In this week's Homerun Slides, part 2 of the Canadian Diabetes Association's specific recommendations for patient-centered diabetes care.

In this week's Homerun Slides, part 4 of the Canadian Diabetes Association's specific recommendations for patient-centered diabetes care.

Novo Nordisk announced positive results on its pipeline GLP-1 candidate, semaglutide, from the phase IIIa trial, SUSTAIN 4 and 5.

In this week's Homerun Slides, the Canadian Diabetes Association lists insulin action and examples of insulin initiation and titration regimens in people with type 2.

Is semaglutide a better way to manage type 2 diabetes?

In this week's Homerun Slides, prioritizing patient characteristics to determine best type 2 treatment agent.

Part 2 of our ADA Rundown checks out the latest information on competing long-acting insulins, and the ongoing research into potential class effect benefits for cardiovascular outcomes: as data shows CV benefits for DPP-4 and SGLT-2 treatments, are GLP-1 treatments under pressure?

In part 1 of our ADA Rundown, we look at cardiovascular benefits for multiple drugs, new combination treatments, and the possibility that Invokana's weight loss benefits may also apply to people who don't have diabetes.

In this week's Homerun Slides, the Canadian Diabetes Association's guidelines for the pharmacologic treatment of type 2 diabetes, which dictate that the choice of therapy depends on glycemia.